The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global single cell multiomics market reached a value of US$ 2.85 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 7.73 Billion by 2027, exhibiting at a CAGR of 17.30% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
Single cell multiomics refers to the analysis of multiple types of molecules from an individual cell to gain insights regarding cellular diversity and heterogenity. It involves single cell genomics, proteomics, transcriptomics and metabolomics and is widely used in neurology, immunology, cell biology and oncology. Single cell multiomics aids in enhancing the understanding of population architectures and cellular properties of heterogeneous tissues. It utilizes single cell isolation and dispensing techniques to provide images of the molecular layers and complex biological structures. In comparison to the traditionally used live-cell fluorescence imaging techniques, single-cell multi-omics does not involve the destruction of cells for analysis and can measure multiple types of the molecule from a single cell. As a result, it is widely used across biotechnology and pharmaceutical organizations, hospitals, academics and research institutes and diagnostic laboratories.
The rising prevalence of chronic diseases, such as cancer and communicable viral diseases, is one of the key factors driving the growth of the market. Single cell multiomics provides a high-resolution landscape of cellular components in the tumors. Additionally, the widespread product adoption for visualization and analysis of cell heterogeneity, tumor micro-environment and antibody development are favoring the market growth. Moreover, various technological advancements, such as the development of single-cell isolation and barcoding technologies that enable deoxyribonucleic acid (DNA), messenger ribonucleic acid (mRNA) and protein profiles to be measured at a single-cell resolution, are providing a thrust to the market growth. In line with this, significant growth in the pharmaceutical industry is positively impacting the market growth. Other factors, including the increasing adoption of personalized medicine for the treatment of genetic disorders, along with the extensive improvements in the healthcare infrastructure, are anticipated to drive the market toward growth.
IMARC Group provides an analysis of the key trends in each sub-segment of the global single cell multiomics market, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on type, product type, technique, application and end user.
Breakup by Type:
Breakup by Product Type:
Breakup by Technique:
Breakup by Application:
Breakup by End User:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being 10x Genomics Inc., Becton Dickinson and Company, BGI Genomics (BGI Group), Bio-RAD Laboratories Inc., Fluidigm Corporation, Illumina Inc., Mission Bio, NanoCellect Biomedical, Nanostring Technologies Inc., Proteona, Takara Bio Inc. (Takara Holdings) and Thermo Fisher Scientific Inc.
|Base Year of the Analysis||2021|
|Segment Coverage||Type, Product Type, Technique, Application, End User, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||10x Genomics Inc., Becton Dickinson and Company, BGI Genomics (BGI Group), Bio-RAD Laboratories Inc., Fluidigm Corporation, Illumina Inc., Mission Bio, NanoCellect Biomedical, Nanostring Technologies Inc., Proteona, Takara Bio Inc. (Takara Holdings) and Thermo Fisher Scientific Inc.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2299
Five User License: US$ 3399
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at